🔗 Share this article

Former Prime Minister Sunak has strengthened his appeal for a targeted screening programme for prostate gland cancer.

In a recently conducted conversation, he stated being "certain of the immediate need" of implementing such a system that would be economical, achievable and "save innumerable lives".

His comments come as the National Screening Advisory Body reconsiders its ruling from half a decade past declining to suggest regular testing.

Media reports indicate the body may continue with its existing position.

Athlete Contributes Voice to Movement

Gold medal cyclist Sir Chris Hoy, who has advanced prostate cancer, advocates for middle-aged males to be screened.

He suggests decreasing the age threshold for accessing a PSA blood test.

Currently, it is not automatically provided to asymptomatic males who are younger than fifty.

The prostate-specific antigen screening is debated though. Readings can rise for factors other than cancer, such as bacterial issues, resulting in misleading readings.

Critics argue this can cause unwarranted procedures and adverse effects.

Focused Screening Proposal

The proposed screening programme would focus on men aged 45–69 with a family history of prostate cancer and men of African descent, who face double the risk.

This population encompasses around 1.3 million individuals individuals in the Britain.

Research projections indicate the system would necessitate twenty-five million pounds a year - or about £18 per person per individual - comparable to intestinal and breast examination.

The assumption includes 20% of suitable candidates would be invited yearly, with a 72% uptake rate.

Diagnostic activity (scans and biopsies) would need to increase by almost a quarter, with only a reasonable growth in medical workforce, as per the study.

Medical Community Response

Various medical experts are sceptical about the value of testing.

They contend there is still a risk that patients will be intervened for the disease when it is potentially overtreated and will then have to experience side effects such as bladder issues and sexual performance issues.

One leading urological specialist commented that "The problem is we can often detect abnormalities that doesn't need to be managed and we risk inflicting harm...and my worry at the moment is that harm to benefit ratio needs adjustment."

Patient Experiences

Individual experiences are also influencing the discussion.

A particular case concerns a man in his mid-sixties who, after seeking a PSA test, was detected with the disease at the time of 59 and was told it had progressed to his hip region.

He has since experienced chemical therapy, radiotherapy and endocrine treatment but cannot be cured.

The individual supports testing for those who are potentially vulnerable.

"That is very important to me because of my sons – they are 38 and 40 – I want them checked as soon as possible. If I had been examined at fifty I am certain I wouldn't be in the position I am currently," he said.

Future Actions

The Screening Advisory Body will have to weigh up the evidence and viewpoints.

While the latest analysis indicates the implications for personnel and availability of a testing initiative would be manageable, some critics have contended that it would redirect imaging resources away from individuals being treated for other conditions.

The ongoing discussion underscores the complex equilibrium between timely diagnosis and potential overtreatment in prostate cancer management.